{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T02:06:09Z","timestamp":1774922769824,"version":"3.50.1"},"reference-count":37,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T00:00:00Z","timestamp":1716768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: This study systematically reviewed the association between metabolic-dysfunction-associated steatotic liver disease (MASLD) and the development of hepatic cancer. Previous research has highlighted MASLD as a predisposing condition. Aim: To collect recent global data on the relationship between MASLD and hepatic cancer. Methods: A systematic review was conducted, which included an analysis of studies on the relationship between MASLD and the incidence of hepatic cancers, focusing on the role of fibrosis and MASLD severity as predictors of cancer risk. Following standard methodological frameworks for the assessment of longitudinal studies, the review gathered information on fibrosis scores, hepatocellular carcinoma (HCC) incidence, and other types of hepatic neoplasms. Results: A total of 522 studies were initially identified, of which 6 studies were appropriate for the review. They collectively revealed that the stage of fibrosis in MASLD is a significant independent predictor of mortality and liver-related events, with higher fibrosis stages correlating with greater risk. Longitudinal data showed that increases in FIB-4 scores were linked to a higher risk of developing HCC and cirrhosis. MASLD was also associated with an increased risk of non-hepatic cancers such as colorectal cancer in males and breast cancer in females. The severity of MASLD was found to be a modifiable risk factor for biliary tract cancer (BTC), with the risk further amplified by diabetes. Moreover, lifestyle factors and comorbidities, such as smoking and diabetes, were identified as modifiers of cancer risk in MASLD patients. Conclusions: The systematic review identified the association between MASLD and an elevated risk of hepatic cancer, establishing a clear link between the severity of liver fibrosis and the incidence of HCC and other hepatic neoplasms. This supports the need for screening for hepatic cancer in patients with MASLD, particularly in the presence of advanced fibrosis or other risk-modifying factors.<\/jats:p>","DOI":"10.3390\/jcm13113132","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:33:31Z","timestamp":1716802411000},"page":"3132","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Association between Metabolic-Dysfunction-Associated Steatotic Liver Disease and Hepatic Cancer: Current Concepts and Future Challenges"],"prefix":"10.3390","volume":"13","author":[{"given":"Husam","family":"Bader","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saif","family":"Yamin","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Jordan, Amman 11942, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5402-8146","authenticated-orcid":false,"given":"Hamzeh","family":"Alshahwan","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Jordan, Amman 11942, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Husam","family":"Farraj","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joud","family":"Maghnam","sequence":"additional","affiliation":[{"name":"School of Medicine, Al-Balqa\u2019 Applied University, Al-Salt 19117, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazan Abu","family":"Abu Omar","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can We Use Old NAFLD Data under the New MASLD Definition?","volume":"80","author":"Song","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease\u2014Meta-analytic Assessment of Prevalence, Incidence, and Outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.25536","article-title":"Outcomes of Curative Treatment for Hepatocellular Cancer in Nonalcoholic Steatohepatitis versus Hepatitis C and Alcoholic Liver Disease","volume":"55","author":"Reddy","year":"2012","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/ajg.2017.5","article-title":"Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data","volume":"112","author":"Kabbany","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/hep.1840360609","article-title":"NAFLD May Be a Common Underlying Liver Disease in Patients with Hepatocellular Carcinoma in the United States","volume":"36","author":"Marrero","year":"2002","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cgh.2015.08.010","article-title":"Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans","volume":"14","author":"Kanwal","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.28719","article-title":"Nonalcoholic Fatty Liver Disease: Epidemiology, Natural History, and Diagnostic Challenges","volume":"64","author":"Cholankeril","year":"2016","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cgh.2020.09.036","article-title":"Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda","volume":"20","author":"Singal","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13643-018-0915-2","article-title":"The Risk of Bias in Observational Studies of Exposures (ROBINS-E) Tool: Concerns Arising from Application to Observational Studies of Exposures","volume":"7","author":"Bero","year":"2018","journal-title":"Syst. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE Guidelines: 3. Rating the Quality of Evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-Term Outcomes of Patients With Nonalcoholic Fatty Liver Disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","article-title":"Longitudinal Changes in Fibrosis Markers Are Associated with Risk of Cirrhosis and Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease","volume":"78","author":"Cholankeril","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","article-title":"Association between Non-Alcoholic Fatty Liver Disease and Cancer Incidence Rate","volume":"68","author":"Kim","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2021.03.024","article-title":"Association between Non-Alcoholic Fatty Liver Disease and the Risk of Biliary Tract Cancers: A South Korean Nationwide Cohort Study","volume":"150","author":"Park","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3748\/wjg.v21.i3.913","article-title":"Association of Nonalcoholic Fatty Liver Disease and Liver Cancer","volume":"21","author":"Schulz","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.cgh.2020.05.009","article-title":"Associations Between Nonalcoholic Fatty Liver Disease and Cancers in a Large Cohort in China","volume":"19","author":"Wang","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1746.2008.05640.x","article-title":"Clinical Features and Outcomes of Cirrhosis Due to Non-Alcoholic Steatohepatitis Compared with Cirrhosis Caused by Chronic Hepatitis C","volume":"24","author":"Yatsuji","year":"2009","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/bjs.9057","article-title":"Fatty Liver Disease as a Predictor of Local Recurrence Following Resection of Colorectal Liver Metastases","volume":"100","author":"Hamady","year":"2013","journal-title":"Br. J. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2741\/1811","article-title":"Matrix Metalloproteinases: Roles in Cancer and Metastasis","volume":"11","author":"Fingleton","year":"2006","journal-title":"Front. Biosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1101\/gad.14.2.163","article-title":"Cell Surface-Localized Matrix Metalloproteinase-9 Proteolytically Activates TGF-Beta and Promotes Tumor Invasion and Angiogenesis","volume":"14","author":"Yu","year":"2000","journal-title":"Genes. Dev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jhep.2004.03.019","article-title":"Transforming Growth Factor-Beta Induces Contraction of Activated Hepatic Stellate Cells","volume":"41","author":"Kharbanda","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/ijc.22594","article-title":"Resident Stromal Cell-Derived MMP-9 Promotes the Growth of Colorectal Metastases in the Liver Microenvironment","volume":"121","author":"Gorden","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_29","first-page":"1069","article-title":"Liver Metastasis Rare in Colorectal Cancer Patients with Fatty Liver","volume":"44","author":"Hayashi","year":"1997","journal-title":"Hepatogastroenterology"},{"key":"ref_30","first-page":"167","article-title":"Relationship between Fatty Liver and Liver Metastasis in Rats given Injection of Rat Colon Cancer Cell Line","volume":"46","author":"Tamura","year":"1999","journal-title":"Hepatogastroenterology"},{"key":"ref_31","first-page":"1541","article-title":"Fatty Liver Suppressed the Angiogenesis in Liver Metastatic Lesions","volume":"47","author":"Karube","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"ref_32","first-page":"1164","article-title":"Lower Incidence of Hepatic Metastases of Colorectal Cancer in Patients with Chronic Liver Diseases: Meta-Analysis","volume":"60","author":"Augustin","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00384-013-1656-2","article-title":"Hepatic Steatosis Is Associated with Lower Incidence of Liver Metastasis from Colorectal Cancer","volume":"28","author":"Murono","year":"2013","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2353\/ajpath.2009.080703","article-title":"High Fat Diet Induced Hepatic Steatosis Establishes a Permissive Microenvironment for Colorectal Metastases and Promotes Primary Dysplasia in a Murine Model","volume":"175","author":"VanSaun","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","article-title":"Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality after Surgery for Hepatic Colorectal Metastases","volume":"24","author":"Vauthey","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.sla.0000193603.26265.c3","article-title":"Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases","volume":"243","author":"Karoui","year":"2006","journal-title":"Ann. Surg."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jhep.2021.08.028","article-title":"Rational HCC Screening Approaches for Patients with NAFLD","volume":"76","author":"Singal","year":"2022","journal-title":"J. Hepatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/11\/3132\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:48:50Z","timestamp":1760107730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/11\/3132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["jcm13113132"],"URL":"https:\/\/doi.org\/10.3390\/jcm13113132","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}